Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes. The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation. Read More
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Thursday. Stay informed about the latest market trends.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 29.9% year on year to $706.3 million. On top of that, next quarter’s revenue guidance ($767.8 million at the midpoint) was surprisingly good and 5.1% above what analysts were expecting. Its non-GAAP profit of $1.24 per share was 8.1% above analysts’ consensus estimates.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025.
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting results this Thursday before market hours. Here’s what investors should know.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new campaign, “The Day Diabetes Showed Up to Work,” in honor of Diabetes Awareness Month, which starts November 1.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert (“Robbie”) L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company’s board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board’s Audit Committee.
Discover how Louis Navellier's growth stock strategy identified Insulet Corp (PODD), a leader in innovative insulin delivery with strong earnings and sales growth.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company’s Acton, Massachusetts headquarters on Thursday, November 20, 2025.
Insulet (NASDAQ: PODD) has outperformed the market over the past 15 years by 10.02% on an annualized basis producing an average annual return of 22.35%. Currently, Insulet has a market capitalization of $21.87 billion.
6 analysts have shared their evaluations of Insulet (NASDAQ: PODD) during the recent three months, expressing a mix of bullish and bearish perspectives.
Insulet Corp (PODD) exemplifies affordable growth with strong revenue & EPS expansion, high profitability, and a valuation justified by its industry-leading potential.
